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Abstract
Background: In HIV-infected patients, prediction of Cytomegalovirus (CMV) disease remains difficult. A protective role of
mannan-binding lectin (MBL) and ficolins against CMV disease has been reported after transplantation, but the impact in
HIV-infected patients is unclear.
Methods: In a case-control study nested within the Swiss HIV Cohort Study, we investigated associations between plasma
levels of MBL/ficolins and CMV disease. We compared HIV-infected patients with CMV disease (cases) to CMV-seropositive
patients without CMV disease (controls) matched for CD4 T-cells, sampling time, and use of combination antiretroviral
therapy. MBL and M-ficolin, L-ficolin, and H-ficolin were quantified using ELISA.
Results: We analysed 105 cases and 105 matched controls. CMV disease was neither associated with MBL (odds ratio [OR]
1.03 per log10 ng/mL increase (95% CI 0.73–1.45)) nor with ficolins (OR per log10 ng/mL increase 0.66 (95% CI 0.28–1.52),
2.34 (95% CI 0.44–12.36), and 0.89 (95% CI 0.26–3.03) for M-ficolin, L-ficolin, and H-ficolin, respectively). We found no
evidence of a greater association between MBL and CMV disease in patients with low CD4 counts; however in the
multivariable analysis, CMV disease was more likely in patients with an increased HIV RNA (OR 1.53 per log10 copies/mL;
95% CI 1.08–2.16), or a shorter duration of HIV-infection (OR 0.91 per year; 95% CI 0.84–0.98).
Conclusions: CMV disease is not associated with low levels of MBL/ficolins, suggesting a lack of a protective role in HIV-
infected patients.
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Introduction
Cytomegalovirus (CMV) latently infects up to 70% of the
general population [1]. To achieve control of CMV replication
and prevent tissue-invasive CMV disease CMV-specific T-cells are
essential. In patients with prolonged immunosuppression, substan-
tial reduction of CMV-specific T-cells is associated with an
increased risk for CMV reactivation, progressive replication and
disease [2]. HIV-infection leads to both a significant reduction of
CD4 T-cell counts and exhaustion of CD8 T-cell function. The
decline of CD4 T-cells below 100 cells/mL serves as a surrogate
marker for an advanced state of immunosuppression and an
increased risk of CMV disease [3,4]. Significant reductions of
CMV-specific T-cells have been described in such advanced states
of immunosuppression [5]. In addition, CMV disease is rare
during antiretroviral treatment and after stable immune recovery.
Nevertheless, in HIV-infected patients the impact of CMV-specific
CD4 T-cells on CMV replication remains controversial. The







































increase of overall CD4 T-cell frequencies was associated with
significantly less CMV disease [6]. However, Singh and colleagues
reported a reduction of CMV-specific CD8 T-cells in individuals
with a history of CMV disease, despite normal CD4 T-cell
reconstitution [7]. In addition, CMV-specific T-cells were shown
to poorly predict CMV retinitis in HIV-AIDS patients [8],
suggesting a potential role for other (immunological) co-factors. In
clinical states with impaired adaptive immunity such as transplan-
tation or HIV-infection, the innate immune response may become
a more decisive factor in enabling the host to gain control over
virus replication.
Mannan-binding lectin (MBL) and ficolins are components of
the innate immune response and are integral in complement
pathway activation. MBL, an oligomer of homo-trimeric protein
subunits synthesised in the liver, binds in its oligomeric form to
carbohydrates on bacteria, fungi, and viruses [9,10,11]. MBL has
been found to bind directly to virions from a number of different
virus families, including human immunodeficiency virus [12],
severe acute respiratory syndrome coronavirus [13], Influenza A
virus [13], Ebola virus [13], dengue virus [13], and West Nile virus
[13]. This interaction subsequently was shown to lead to
neutralization by deposition of complement C3 and C4 on the
virus subsequently preventing the interaction of the virus with the
host cell and leading to increased phagocytosis or lysis of the virus
[14,15]. With regard to CMV, evidence of involvement of the
lectin pathway is controversial. CMV glycoproteins are potential
targets for MBL binding which could prevent virion entry into
host cells. Alternatively, MBL could recognize these glycoproteins
in/on the surface of an infected cell subsequently inducing
complement-mediated cell destruction of the viral reservoir
(infected cells) [16,17]. In contrast, in a previous study comple-
ment activation and C3 deposition on the surface of CMV infected
human skin fibroblasts were not dependent on MBL but only on
C1q, the initiating molecule of the classical pathway of comple-
ment [18]. Similar to MBL, M-ficolin (ficolin-1), L-ficolin (ficolin-
2), and H-ficolin (ficolin-3) also show oligomers of trimeric
subunits and utilize the same activation enzymes [19,20].
However, the effects of MBL and ficolin activation are complex
and not fully understood. Intriguingly, many viruses encode
homologues of complement regulatory proteins, which interact
with complement receptors. These virus-induced alterations of
complement function may increase virus persistence and limit
immune-mediated tissue destruction [14,21,22]. Thus, comple-
ment may play a role in both innate and adaptive anti-viral
immune responses [23].
MBL levels show only very limited acute phase changes [24,25],
and thereby a one-time measurement might be sufficient to
determine life-long plasma levels. Interestingly, up to one third of
the general population carry genetic polymorphisms associated
with functional MBL deficiencies [26,27]. Thus, whereas ficolin
deficiencies are rare, MBL deficiencies may constitute the most
common immune deficit in humans [28]. Functional deficiencies
of MBL were found to be associated with an increased risk for
CMV disease in recipients of solid organ and hematopoietic stem
cell transplants [9,29,30,31,32,33].
However, data on the role of functional MBL deficiency due to
MBL polymorphisms in transplant patients with CMV replication
are conflicting [9,29,30,31,32,33,34,35]. This highlights the need
to further define the impact of functional MBL deficiency in
different populations with impaired immune function. The
relevance of MBL and ficolins in HIV-infected patients with
respect to CMV disease is unknown.
We hypothesised that functional MBL deficiency is a risk factor
for CMV disease in HIV patients and therefore that HIV-infected
patients with CMV disease have lower serum MBL and ficolin
levels when compared to matched HIV-infected individuals with
CMV antibodies but without CMV disease. Furthermore, MBL
and ficolins might confer enhanced protection against CMV
disease as immunodeficiency increases.
Patients and Methods
We conducted a matched case-control study, which was nested
within the Swiss HIV Cohort Study (SHCS, main centres Basel,
Bern, Geneva, Lausanne, Lugano, St. Gallen, and Zu¨rich;
described in detail elsewhere [36]). We determined plasma levels
of MBL (primary exposure variable) and M-ficolin (ficolin-1), L-
ficolin (ficolin-2), and H-ficolin (ficolin-3) respectively (secondary
exposure variables). Two groups of patients were compared: HIV-
infected patients with CMV disease (cases), and HIV-infected
individuals with CMV antibodies but without CMV disease
(controls). Patients with other concurrent opportunistic diseases
were not excluded.
Ethics Statement
All patients gave written informed consent to the enrolment into
the SHCS (http://www.shcs.ch). This study was evaluated
through the scientific committee of the SHCS (project number
637). Subsampling of DNA material to detect genetic differences
between CMV cases and their matched controls was envisaged;
however, because genetic informed consent was introduced only in
July 2001, the availability of DNA was primarily driven by year of
consent. For each consenting patient, we selected a DNA sample
closest to the index date (the CMV disease date).
Selection of Cases and Controls
Eligible cases were patients with incident CMV disease (for
definitions see below). Cases were required to have both a CD4 T-
cell count measurement and a concurrent plasma sample taken
within 90 days of the date when CMV disease was first reported
(the index date). Where available CD4 T-cell counts and plasma
samples collected at least 6 months before or after the index date
were analysed for MBL and ficolin levels but neither was essential
for inclusion in the study. Cases at the index date were classified
into one of four treatment groups: no combination antiretroviral
therapy (cART) use (‘‘naı¨ve group’’), on continuous cART for less
than 6 months (‘‘new cART group’’), on continuous cART for
more than 6 months (‘‘stable cART group’’) or on/off cART
(‘‘unstable cART group’’), where cART was defined as use of at
least three antiretroviral agents. Patients on suboptimal cART
(mono or dual therapy) at the index date were included in the
naı¨ve group. After an interruption to therapy for more than 6
months patients were considered to be naı¨ve once again.
Eligible controls were positive for IgG anti-CMV, conferring a
risk for CMV reactivation. Patients were not eligible as controls
after starting a treatment known to have CMV anti-viral activity
(val2/acyclovir, cidofovir, entecavir, famciclovir, foscarnet, val2/
ganciclovir, interferon alpha, peginterferon alpha, ribavirin or
telbivudine). However, they became eligible again 30 days after
discontinuation of the anti-viral treatment. Controls were a
random sample of all those at risk for CMV disease at the time
when the index case was detected (and could include the case itself,
those that were cases at a later date, or those acting as controls for
other cases; [37]).
We used 1:1 matching, i.e., we randomly sampled one control
for each case. Controls were additionally matched for CD4 T-cell
count (values within 615 cells/mL of the index case), and for
cART treatment classification as one of the four groups (see
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above). We used matching to ensure adjustment for CD4 T-cell count
and cART classification and to allow us to consider homogeneity of
the association between CMV disease and MBL across CD4 T-cell
count strata. As with cases, where available control CD4 T-cell counts
and plasma samples collected at least 6 months before or after the
index date were analysed for MBL and ficolin levels.
Definitions and Endpoints
Infectious outcomes were classified according to previously
published criteria ([2] and http://www.shcs.ch/56-definitions#4.
5.3). ‘‘CMV disease’’ included CMV retinitis and other end-organ
involvement excluding liver, spleen and lymph node disease. CMV
infections of the liver, lymph nodes and spleen were not considered
as these rare diseases are excluded in the CDC AIDS defining
conditions (http://www.cdc.gov/mmwr/preview/mmwrhtml/
rr5710a2.htm). Case definitions were according to international
and standardized criteria and this guarantees a high level of
diagnostic accuracy. Definitive CMV retinitis was diagnosed by
characteristic ophthalmological appearance, CMV-detection by
polymerase chain reaction (PCR), and response to CMV
treatment. However, in older cases (.10 years) the code
‘‘definitive’’ CMV retinitis is related to previous CDC-definitions
that did not require PCR. Presumptive CMV retinitis was
diagnosed by characteristic appearance on ophthalmoscopic
examination (discrete patches of retinal whitening with distinct
borders spreading in a centrifugal manner, frequently associated
with retinal vasculitis, haemorrhage and necrosis) and typical
findings following the resolution of active disease (residual retinal
scarring and atrophy with retinal pigment epithelial mottling).
Invasive CMV disease at other sites was always definitive with
histologically proven CMV-infection. A positive culture alone
from any site (except cerebrospinal fluid) without histological
evidence of invasive disease was not considered sufficient for the
diagnosis of CMV disease.
Determination of MBL and M- (1), L- (2) and H-ficolin (3)
Levels and MBL Genotyping
For each parameter, all samples were thawed and analysed
simultaneously. MBL, and L-ficolin, H-ficolin levels were quan-
tified using commercially available ELISA kits (MBL: BioportoH,
Denmark; H- and L-ficolin: Hycult BiotechnologyH, Netherlands).
All assays were performed following the manufacturer’s instruc-
tions. Levels of M-ficolin were determined using an in-house time-
resolved immunofluorometric assay developed by Wittenborn
et al. as previously published [38]. In brief, wells were coated with
monoclonal anti-M-ficolin, incubated with samples diluted in a
high ionic strength buffer with EDTA, heat aggregated human
IgG and bovine IgG, washed and developed with biotinylated
anti-M-ficolin antibody followed by europium-labelled streptavi-
din, and read on a time-resolved fluorometer.
MBL genotyping was performed as previously described [39].
Power Calculations
Conditional logistic regression is appropriate to assess the
association between CMV disease and plasma MBL in a study
Table 1. Patient characteristics for included and excluded cytomegalovirus (CMV) disease cases.
Characteristic Measure or category Included cases Excluded cases
(n =105) (n =674)
Age, years Median 37 37
(IQR) (32–44) (32–45)
Gender, % Male 70 82
Female 30 18
CMV disease1, % Not liver, spleen or lymph nodes 49 43
Retinitis 51 57
Stage of infection2, % CDC group A 13 11
CDC group B 11 12
CDC group C 75 77
Duration of HIV-infection3, years Median 4.9 3.0
(IQR) (0.5–8.1) (1.3–6.1)
Other concurrent opportunistic infections4, % Yes 11 16
No 89 84
History of cART use, % Naı¨ve 59 92
New cART 18 5
Stable cART 6 1
Unstable cART 17 3
Abbreviations: IQR, interquartile range; CMV, cytomegalovirus; HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; IRIS, immune
reconstitution inflammatory syndrome.
1Cases diagnosed with both ‘‘CMV not liver, spleen or lymph nodes’’ and ‘‘CMV retinitis’’ are counted as the former (n = 2 and n = 20 for included and excluded CMV
disease cases respectively).
2These statistics represent the clinical stage a patient had prior to the index date.
3Based on the date of (for included and excluded CMV disease cases respectively): a first documented positive test (49%, 39%), a first reported positive test (33%, 38%)
or the cohort registration visit (18%, 22%).
4Herpes simplex disease, mucocutan. Herpes simplex ulceration, herpes zoster multidermatomal or relapse, disseminated toxoplasmosis, toxoplasmosis retinitis or
toxoplasmosis of the brain within 690 days of the index date.
doi:10.1371/journal.pone.0051983.t001
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with matched pairs [40]. Assuming a common standard deviation
regarding MBL among matched sets and a 1-sided type I error
rate of 2.5%, with 126 cases and their 126 matched controls a
power of 80% could be achieved to detect an odds ratio for CMV
disease of 1.4 per standard deviation unit decrease in MBL [41].
Statistical Analyses
We used conditional logistic regression to estimate associations
between CMV disease and plasma MBL/M- (1), L- (2), or H-
ficolin (3). In univariable analyses, we estimated the associations
between CMV disease and the four individual proteins, unadjust-
ed for covariates other than the matching factors. In the
Table 2. Patient characteristics for included cases and their controls.
Characteristic Measure or category Cases Controls
(n=105) (n=105)
Age, years Median 37 37
(IQR) (32–44) (33–42)
Gender, % Male 70 74
Female 30 26
CMV disease1, % Not liver, spleen or lymph nodes 49
Retinitis 51
Stage of infection2, % CDC group A 13 11
CDC group B 11 31
CDC group C 75 57
Duration of HIV-infection3, years Median 4.9 5.5
(IQR) (0.5–8.1) (2.3–10.1)
HIV RNA4, log10 copies/mL Median 5.0 4.4
(IQR) (4.1–5.4) (3.0–5.2)
CD4 T-cell count5, cells/mm3 Median 20 22
(IQR) (10–61) (10–65)
CD8 T-cell count, cells/mm3 Median 396 516
(IQR) (214–648) (290–838)
Other concurrent opportunistic infections6, % Yes 11 5
No 89 95
History of cART use5, % Naı¨ve 59 59
New cART 18 18
Stable cART 6 6
Unstable cART 17 17
MBL, log10 ng/mL Median 3.2 3.1
(IQR) (2.6–3.4) (2.6–3.5)
H-ficolin, log10 ng/mL Median 4.6 4.6
(IQR) (4.4–4.8) (4.3–4.8)
L-ficolin, log10 ng/mL Median 4.3 4.3
(IQR) (4.2–4.4) (4.2–4.4)
M-ficolin, log10 ng/mL Median 3.0 3.1
(IQR) (2.9–3.2) (2.9–3.3)
MBL structural genotype7, % A/A 52 56
A/O 48 40
O/O 0 4
Abbreviations: IQR, interquartile range; CMV, cytomegalovirus; HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; IRIS, immune
reconstitution inflammatory syndrome; MBL, mannan-binding lectin.
1Cases diagnosed with both ‘‘CMV not liver, spleen or lymph nodes’’ and ‘‘CMV retinitis’’ are counted as the former (n = 2).
2These statistics represent the clinical stage a patient had prior to the index date.
3Based on the date of (for included cases and their controls respectively): a first documented positive test (49%, 52%) a first reported positive test (33%, 35%) or the
cohort registration visit (18%, 12%).
4Available in 89 case-control pairs.
5Matching variable.
6Herpes simplex disease, mucocutan. Herpes simplex ulceration, herpes zoster multidermatomal or relapse, disseminated toxoplasmosis, toxoplasmosis retinitis or
toxoplasmosis of the brain within 690 days of the index date.
7Available in 25 case-control pairs.
doi:10.1371/journal.pone.0051983.t002
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multivariable analysis, we assessed the association between CMV
disease and MBL adjusted for additional potentially confounding
risk factors for CMV disease, namely age, gender, HIV RNA and
duration of HIV-infection. For patients without a date of a first
documented or reported positive test, we used the date of the
SHCS cohort registration visit to calculate an approximate
duration of HIV-infection.
A key question for this study was whether MBL confers
enhanced protection against CMV disease as immunodeficiency
increases. To address this question, we added a covariate for the
interaction between CD4 T-cell count and MBL to our model.
The estimate for this interaction shows how the association
between CMV disease and MBL changes at lower CD4 T-cell
counts. In addition, we estimated the association between CMV
disease and MBL depending on CD4 T-cell count. We calculated
CD4 T-cell count strata to separate patients with CD4 T-cell
counts below 20 cells/mL from those with CD4 T-cell counts
above 20 cells/mL.
Earlier studies, which used MBL in categories rather than on a
continuous scale, have suggested a protective role of MBL against
CMV disease in transplant recipients [32]. In an additional
analysis, we therefore represented MBL by a piecewise linear
spline with 2 knots at 100 and 500 ng/mL. Using a piecewise
linear spline allows estimation of the association between CMV
disease and MBL without assuming a continuous gradient across
the entire range of observed MBL levels, but rather below 100, in
between 100 and 500 and above 500 ng/mL.
With plasma samples obtained at least 6 months before or after
the date when CMV disease was first diagnosed not being essential
for patient eligibility, we refrained from formal analyses in order to
avoid a possible selection bias but rather plotted profiles from past
measurements through index date measurements and measure-
ments after the index date. Sub-cohort genetic data were
summarised using descriptive statistics.
For each analysis, we report an estimate of the odds ratio with
95% confidence interval assessing the association between CMV
disease and MBL/ficolin levels. We used SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA) for our analyses; and for graphics, we
used R version 2.14.2 (R Foundation for Statistical Computing,




As of May 2010, 779 cases of incident CMV disease were
documented in the Swiss HIV Cohort Study (SHCS). Of these,
126 (16%) patients had both a CD4 T-cell count measurement
within 690 days of the date of CMV disease diagnosis, in addition
to a concurrently drawn plasma sample. Ultimately, plasma
samples could be retrieved for 105 (13%) cases, with a first episode
of CMV disease between January 1995 and October 2008, and for
their 105 matched controls. These patients were included in the
study and corresponding plasma samples analysed for MBL and
Figure 1. Density plots of the distribution of mannan-binding lectin (MBL), H-ficolin (3), L-ficolin (2), and M-ficolin (1) levels among
cases (solid line) and controls (dashed line), with marker levels given in ng/mL.
doi:10.1371/journal.pone.0051983.g001
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ficolin levels. Excluded cases, with a first episode of CMV disease
between March 1985 and November 2009, had on average a
shorter duration of HIV-infection, and were more likely to be male
with no prior exposure to cART (Table 1).
Patient characteristics for included cases and their controls are
summarised in Table 2. Cases were predominantly male with a
median age of 37 years (interquartile range [IQR] 32–44). CMV
retinitis (51%) was the most important location among cases. Two
patients with CMV retinitis had concurrent involvement of other
end-organ sites. Fifteen patients diagnosed with CMV retinitis had
a presumptive diagnosis only, one of whom also had simultaneous
extra-retinal disease. More than half of the patients had no history
of prior exposure to cART; median CD4 T-cell count was 20
cells/mL. According to the CDC classification system for HIV-
infected patients, 75% of the cases were classified as having CDC
stage C. Cases had on average a shorter duration of HIV-infection
and lower CD8 T-cell count compared with their controls, but
higher HIV RNA levels.
MBL and Ficolin Levels in Patients with and without CMV
Disease
MBL levels appeared stable over the range of age of stored
samples (in years) for both cases and controls, giving no cause for
concern about the quality and stability of stored plasma samples
(data not shown). We used September 1st 2010 to calculate an
approximate age of plasma samples, although plates were tested
over a time span of two weeks and a second set was tested in
October 2010.
At the time of first diagnosis of CMV disease the median MBL
level for cases was 1,535 ng/mL (IQR 357–2,465). The median
M-ficolin, L-ficolin, and H-ficolin levels were 1,008 ng/mL (IQR
723–1,722), 19,248 ng/mL (IQR 14,835–26,232) and 36,546 ng/
mL (IQR 22,880–57,054) respectively. Controls had a median
MBL level of 1,228 ng/mL (IQR 370–3,196), with median M-
ficolin, L-ficolin and H-ficolin levels of 1,183 ng/mL (IQR 797–
1,872), 19,068 ng/ml (IQR 15,201–24,784) and 37,391 ng/mL
(IQR 21,595–57,884) respectively. Density plots of MBL and M-
ficolin, L-ficolin and H-ficolin levels showed comparable distribu-
tions among cases and controls (Figure 1).
In univariable conditional logistic regression, no associations were
found between CMV disease and any one of MBL, M-ficolin, L-
ficolin, or H-ficolin (Table 3a). Similarly, having adjusted for
potentially confounding risk factors for CMV disease other than those
considered as matching variables, no association was found between
CMV disease and MBL (Table 3b). The multivariable analysis was
based on 89 case-control pairs without missing data regarding any of
the considered potentially confounding risk factors for CMV disease
(age, gender, HIV RNA level and duration of HIV-infection). CMV
disease was more likely in females (OR 2.13; 95% CI 0.84–5.41), and
with increasing HIV RNA level (OR 1.53 per log10 copies/mL; 95%
CI 1.08–2.16), but less likely with increasing duration of HIV-
infection (OR 0.91 per year; 95% CI 0.84–0.98).
In the present analysis, there was no evidence that MBL is a
more important immunological risk factor for CMV disease in
patients with CD4 T-cell counts below 20 cells/mL (OR for
interaction 0.74; 95% CI 0.35–1.53). The estimated ORs were
1.26 per log10 ng/mL (95% CI 0.69–2.28) and 0.92 per log10 ng/
mL (95% CI 0.60–1.41) for patients with CD4 T-cell counts above
and below 20 cells/mL respectively (Table 3c). With the linear
spline model representing the functional relationship between
CMV disease and MBL by three different (below 100, in between
100 and 500, and above 500 ng/mL) as opposed to one single
continuous gradient, no association was found between CMV
disease and MBL either (Table 3d).
Plasma levels of MBL and all three ficolins appeared stable over
the range of past (available in 34 (32%) cases and 50 (48%)
controls) through at and after (available in 68 (65%) cases and 80
(76%) controls) disease date measurements in both cases and their
matched controls (Figure 2). MBL levels did not appear to follow
a typical pattern of acute-phase response with up-regulation
during CMV disease. Prior to the index date, no phase of reduced
MBL or ficolin levels was observed.
Structural MBL genotypes were available for 25 matched pairs,
with similar distribution among cases and controls (Table 2).
We carried out a supplementary analysis to compare cases and
controls with regard to MBL/ficolins by type of CMV disease.
The median MBL level (log10 ng/ml) for cases of CMV retinitis
(n = 54) and their controls was 3.2 (IQR 2.5–3.4) and 3.1 (2.7–3.6),
respectively. Cases of other end-organ CMV disease (not liver,
spleen or lymph nodes; n = 51) and their controls had a median
MBL level (log10 ng/ml) of 3.2 (IQR 2.6–3.4) and 3.1 (IQR 2.4–
3.4), respectively. A similar pattern of no obvious differences was
seen for H-, L-, and M-ficolin.
Discussion
To the best of our knowledge this is the first study on the
potential link between MBL and CMV disease in HIV-infected
Table 3. Associations between cytomegalovirus (CMV)
disease and mannan-binding lectin (MBL)/ficolin levels.
Effect Odds ratio 95% CI
A
MBL, log10 ng/mL 1.03 0.73–1.45
H-ficolin, log10 ng/mL 0.89 0.26–3.03
L-ficolin, log10 ng/mL 2.34 0.44–12.36
M-ficolin, log10 ng/mL 0.66 0.28–1.52
B
MBL, log10 ng/mL 0.85 0.55–1.30
Age1, years 1.03 0.67–1.59
Female gender 2.13 0.84–5.41
HIV RNA, log10 copies/mL 1.53 1.08–2.16
Duration of HIV-infection, years 0.91 0.84–0.98
C
Effect of MBL per log10 ng/mL
CD4 T-cell count #20 cells/mm3 0.92 0.60–1.41
CD4 T-cell count .20 cells/mm3 1.26 0.69–2.28
D
Effect of MBL per 100 ng/mL
#100 ng/mL 0.71 0.12–4.15
100–500 ng/mL 1.17 0.83–1.65
.500 ng/mL 0.99 0.96–1.01
Abbreviations: MBL, mannan-binding lectin; CI, confidence interval.
1Per 10 years increase.
A) Univariable conditional logistic regression models for MBL, H-ficolin (3), L-
ficolin (2) and M-ficolin (1). B) Multivariable conditional logistic regression
model for MBL adjusted for the effects of potentially confounding risk factors
for CMV disease based on 89 case-control pairs without missing data. C)
Conditional logistic regression model for MBL, investigating its relationship with
CD4 T-cell count. D) Conditional logistic regression model with a linear spline
for MBL.
doi:10.1371/journal.pone.0051983.t003
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patients. In a nested case-control study we compared 105 HIV-
infected patients with histologically proven tissue-invasive CMV
disease to a well-matched control group at risk of CMV
reactivation (positive CMV-IgG, low CD4 T-cell count). Our
study shows that low MBL and serum ficolin levels are not
associated with an increased risk for CMV disease in HIV-infected
patients. Our results further suggest that the association between
MBL and CMV disease does not depend on CD4 T-cell count.
However, CMV disease was more prevalent with increasing HIV
RNA level and, surprisingly, less prevalent with increasing time
since HIV-infection.
A major strength of this study is the large number and high
quality of samples available from the multi-center SHCS. Patient
samples and clinical information were prospectively collected
through dedicated teams of infectious diseases specialists and HIV
study nurses. In the SHCS, the diagnostic criteria for CMV
disease, either CMV retinitis or CMV disease at other sites,
require detection by PCR and/or histological proof of tissue-
invasive disease. Therefore a high level of diagnostic accuracy is
guaranteed. Our study is tightly matched with respect to
immunological confounders. CD4 T-cell counts differed only by
a maximum of 15 cells/mL, and cART utilisation was matched
leading to a well-matched composite state of immunosuppression
in cases and controls. The matching criteria allowed us to control
for potential confounders of the adaptive immune response.
While we could not identify an association between low plasma
MBL levels and CMV disease in HIV-infected individuals, the
impact of MBL deficiency as a risk factor for CMV disease in
immunosuppressed individuals remains controversial. In children
with presumed primary CMV-infection, genotypes associated with
lower MBL levels were more frequently observed in patients with
active replication [43]. Another study failed to find a correlation
between CMV replication in newborns and the frequencies of
MBL genotypes [44]. After transplantation several studies have
highlighted MBL deficiency as a potential risk factor for CMV
replication and disease [29,31,32,45,46]. Manuel et al. reported an
increased risk of CMV disease in a small study of high-risk CMV
sero-negative recipients of CMV sero-positive kidney grafts with
functional MBL deficiency [31]. The presence of MBL and ficolin-
2 polymorphisms in the liver and lung transplant recipients were
associated with increased CMV replication in the recipient
[29,45,46]. However, in other transplant cohorts, either structural
haplotype AA had higher rates of CMV disease compared to
patients with A/O or O/O [34]. In addition, MBL and MASP-2
measurements were similar in patients with and without post-
transplant CMV replication [35]. None of the studies discussed
effects of immunosuppression as a potential confounder. In
addition, studies showed higher proportions of functional MBL
deficiency in transplantation compared to healthy individuals
[47,48], implying selection biases.
Figure 2. Mannan-binding lectin (MBL), H-ficolin (3), L-ficolin (2) and M-ficolin (1) levels over time for 105 case-control pairs
included in this study. Time is relative to the index date, with pre and post disease measurements being optional; marker levels are given in ng/mL
on a log10 scale. The smooth curves are local averages found using the default loess smoother in R (R Foundation for Statistical Computing, Vienna,
Austria).
doi:10.1371/journal.pone.0051983.g002
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Ficolin deficiencies have been associated with an increased risk
for bacterial infection. Munthe-Fog et al. described a case of a
homozygous H-ficolin deficient patient with no detectable ficolin
level and recurrent infections, suggesting a role for ficolin in the
control of bacterial infection. In our study only one patient showed
an H-ficolin level below 100 ng/mL. A functional protective
threshold for ficolins has not yet been determined. Although we
have not powered our study to determine a predictive threshold
for CMV disease, our data does not indicate an association
between M-ficolin, L-ficolin, and H-ficolin levels and CMV
disease.
Our study presents some limitations. Patients with concurrent
opportunistic infections other than CMV disease were not
excluded from the control group. With regard to the occurrence
of opportunistic infections in cases versus controls we could not
observe an apparent dysbalance between both patient groups. In
HIV-infected patients, CMV retinitis is the most common
manifestation of CMV disease, whereas this disease entity is
extremely rare in transplant recipients [49]. A large increase in
vitreous MBL levels in patients with endophthalmitis and retinal
vasculitis has been described compared to non-inflamed eyes [50].
Although speculative, this suggests that MBL levels in general
might be lower in the eye and therefore biologically not active
against CMV. Our study was not designed to assess differences in
MBL and ficolin levels between cases with CMV retinitis and
those with other disease localisation. Another limitation is the lack
of information on CMV viremia and CMV replication dynamics
in the context of MBL levels. Indeed, patients with high CMV
viremia do show an increased risk for CMV retinitis and might
benefit from a pre-emptive antiviral therapy [51]. CMV disease,
particularly CMV retinitis and CMV colitis, is often associated
with absent or low level CMV viremia/antigenemia. However,
other studies reported a poor positive and negative predictive
value of CMV viremia in regard of CMV disease [52,53,54]. In
this study, we focused on ‘‘CMV disease’’ as a clinical important
outcome. A prospective study might address the association
between viremia and MBL in more details.
CMV-specific T-cells are known to prevent progression of
CMV replication to CMV disease in immunosuppressed hosts
[55]. We have not measured CMV-specific CD4+ and CD8+ T-
cell responses, however this important co-factor should be
included in future prospective studies.
In summary, our results suggest that low plasma MBL and
ficolin levels are not associated with an increased risk of CMV
disease in patients with HIV.
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